WO2023194913 - IMMUNOGENIC COMPOSITION USEFUL FOR VACCINATION AGAINST ROTAVIRUS
National phase entry:
Publication Number
WO/2023/194913
Publication Date
12.10.2023
International Application No.
PCT/IB2023/053433
International Filing Date
04.04.2023
Title **
[English]
IMMUNOGENIC COMPOSITION USEFUL FOR VACCINATION AGAINST ROTAVIRUS
[French]
COMPOSITION IMMUNOGÈNE UTILE POUR LA VACCINATION CONTRE LES ROTAVIRUS
Applicants **
BOEHRINGER INGELHEIM VETMEDICA GMBH
Inventors
PATTERSON, Abby, Rae
ANSTROM, David, Michael
HAIWICK, Gregory, Brian
JOHNSON, Wesley, Scott
JORDAN, Dianna M. Murphy
NICHOLSON, Bryon
VAUGHN, Eric, Martin
WIDENER, Justin
Priority Data
63/362,488
05.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3210 | |
| EPO | Filing, Examination, Granting | 16788 | |
| Japan | Filing, Examination, Granting | 2533 | |
| South Korea | Filing, Examination, Granting | 2824 | |
| USA | Filing, Examination, Granting | 8240 |
Total:
33,595
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to immunogenic compositions comprising recombinantly constructed polypeptides useful for preparing vaccines, in particular for reducing one or more clinical signs caused by a rotavirus infection. More particular, the present invention is directed to an immunogenic composition containing (i) a fusion protein comprising in N- to C-terminal direction (A) an immunogenic fragment of a rotavirus VP8 protein and (B) an immunoglobulin Fc fragment such as, for example, an IgG Fc fragment, and (ii) an immunogenic substance, different from said fusion protein, wherein said immunogenic composition is usable in a method of reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in swine.[French]
La présente invention concerne des compositions immunogènes comprenant des polypeptides construits par recombinaison utiles pour préparer des vaccins, en particulier pour réduire un ou plusieurs signes cliniques provoqués par une infection à rotavirus. Plus particulièrement, la présente invention concerne une composition immunogène contenant (i) une protéine de fusion comprenant dans la direction N- à C-terminale (A) un fragment immunogène d'une protéine VP8 de rotavirus et (B) un fragment Fc d'immunoglobuline tel que, par exemple, un fragment Fc d'IgG, et (ii) une substance immunogène, différente de ladite protéine de fusion, ladite composition immunogène étant utilisable dans une méthode pour réduire un ou plusieurs signes cliniques, la mortalité ou l'excrétion fécale provoquée par une infection à rotavirus chez le porc.